CurrentColorado Rocky Mountain Health PlansPolicy 2026D0071O

Crysvita Burosumab Twza

Defines medical necessity criteria, initial and continuation authorization requirements, applicable provider specialties, dosing conformity to FDA labeling, and applicable HCPCS/ICD-10 codes for burosumab (Crysvita) for XLH (age ≥6 months) and FGF23-related hypophosphatemia in TIO (age ≥2 years) within UnitedHealthcare Commercial and Individual Exchange plans.

Policy Summary

PayerColorado Rocky Mountain Health Plans

PolicyCrysvita Burosumab Twza

Policy CodePolicy 2026D0071O

Change TypeTemplate update / administrative

Effective DateMay 1, 2026

Next Review Date

Key ActionFor initial authorization, document diagnosis, age criteria, specialty prescribing/consultation, biochemical parameters (e.g., fasting serum phosphorus below age normal), and ensure dosing follows FDA labeling; initial authorization limited to ≤12 months.

SourceLink

POLICY UPDATE CHANGES

Transferred content to shared policy template that applies to both UnitedHealthcare Commercial and Individual Exchange benefit plans and added Application section.

Template Update effective 05/01/2026

2Covered Indications

12Max initial auth (months)

6 moMin age - XLH

2 yrs

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.